SOURCE: The Bedford Report

The Bedford Report

August 30, 2010 09:30 ET

Drug Manufacturers - How Will Expiring Drug Patents Affect Companies in the Healthcare Sector?

Note to Editors: The Following Is an Investment Opinion Being Issued by The Bedford Report

TORONTO--(Marketwire - August 30, 2010) - The Bedford Report examines the outlook for companies in the Drug Manufacturers - Major Industry and has released analyst reports on Pfizer Inc. (NYSE: PFE) & Abbott Laboratories (NYSE: ABT). Access to the full company reports can be found at

In recent quarters, expiring patents in the product lines of the major pharmaceutical companies has become a hot topic. Over the next five years drug companies are expected to lose several patents. In order to compensate for expiring drug patents drug companies have been focusing on mergers and acquisitions in order to shore up their patent lines.

Like you, we realize that timing is everything. We release daily market updates so you can stay ahead of the crowd and make the best investment decisions to maximize your returns. Take a few minutes to register with us for free at and get exclusive access to our numerous analyst reports and industry newsletters.

In future quarters it is expected that sales growth will be primarily driven by emerging markets in the developing world. UBS analysts recently announced that it is expected that developing nations will account for more than 70% of growth in drug sales, and the time is now for companies to focus efforts on these markets.

In recent earnings announcements Pfizer reported Earnings per Share of $0.62 on revenues of $17.3 billion, beating analyst estimates. Abbott Laboratories reported Earnings per Share of $0.83 on revenues of $8.8 billion, seeing double digit percentage gains in both.

Investors can get copies of the full analyst reports on Pfizer and Abbott Laboratories by registering for free at

The Bedford Report has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: 

Contact Information